Free White Paper
Beyond The Obvious: Managing Business Risks During Life Science M&A Due Diligence
Inside this White Paper
The life sciences sector faces a substantial risk of value destruction in mergers and acquisitions (M&A), with failure rates ranging from 60% to 80%. To mitigate these risks, it is crucial to conduct thorough due diligence that goes beyond basic compliance checks. This should encompass strategic, cultural, and technical evaluations to identify and address potential pitfalls prior to finalizing a deal. By implementing a comprehensive approach to due diligence, companies can significantly improve their chances of successful integration and value creation after M&A activities.